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Abstract
Carbamoylphosphate synthetase 1 (CPS1) deficiency is a rare inborn error of
metabolism leading often to neonatal onset hyperammonemia with coma and
high mortality. The biochemical features of the disease are nonspecific and
cannot distinguish this condition from other defects of the urea cycle, namely
N-acetylglutamate synthase deficiency. Therefore, molecular genetic investiga-
tion is required for confirmation of the disease, and nowadays this is done with
increasing frequency applying next-generation sequencing (NGS) techniques.
Our laboratory has a long-standing interest in CPS1 molecular genetic investi-
gation and receives samples from centers in Europe and many other countries.
We perform RNA-based CPS1 molecular genetic investigation as first line
investigation and wanted in this study to evaluate our experience with this
approach as compared to NGS. In the past 15 years, 297 samples were ana-
lyzed, which were referred from 37 countries. CPS1 deficiency could be con-
firmed in 155 patients carrying 136 different genotypes with only a single
mutation recurring more than two times. About 10% of the total 172 variants
comprised complex changes (eg, intronic changes possibly affecting splicing,
deletions, insertions, or deletions_insertions), which would have been partly
missed if only NGS was done. Likewise, RNA analysis was crucial for correct
interpretation of at least half of the complex mutations. This study gives
highest sensitivity to RNA-based CPS1 molecular genetic investigation and
underlines that NGS should be done together with copy number variation
analysis. We propose that unclear cases should be investigated by RNA
sequencing in addition, if this method is not used as the initial diagnostic
procedure.
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1 | INTRODUCTION
Carbamoylphosphate synthetase 1 (CPS1, E.C. 6.3.4.16)
catalyzes, as first and rate-limiting reaction of the urea
cycle, the entry of ammonia into the cycle. This enzyme
is encoded by CPS1 (MIM *608307), located on chromo-
some 2q35 and composed of 38 exons leading to a 1500
amino acid protein.1-3 Mutations in CPS1 can result
in reduced or absent enzyme function leading to
hyperammonemia and other features of CPS1 deficiency
such as neonatal or late onset encephalopathy with
vomiting, seizures, and coma if left untreated (CPS1D,
MIM #237300).4 Diagnosis of CPS1D is based on a bio-
chemical profile with increased plasma ammonia,
decreased plasma citrulline, and a normal or low orotic
acid in urine. Confirmation of the diagnosis requires
either enzyme analysis in liver or small intestinal tissue
or, recommended as method of choice, molecular
genetic investigation.5,6
More than 230 CPS1 mutations are currently
reported.7-15 Molecular genetic investigation for CPS1D
can use different methods: exon per exon sequencing
(direct Sanger sequencing), next generation sequencing
(NGS) as part of a (often custom-made) gene panel or
whole exome or whole genome sequencing with or
without the analysis of copy number variation (CNV),
and RNA analysis.16-18
While automated sequencing applying NGS became
more widely available in recent years and showed
improved detection rates if compared to direct Sanger
sequencing,19 our laboratory performed in most cases
RNA analysis for the confirmation of CPS1D.6,16 Source
of RNA can be liver tissue but also skin fibroblasts17 or,
hereby improving the turn-around time, peripheral lym-
phocytes that were stimulated with phytohemagglutinin
hereby applying a straightforward and less invasive pro-
tocol.16 Advantage of the latter approach is its simplicity
and an improved sensitivity since, for instance, deletions
or insertions caused by intronic changes are picked up in
addition as their effect on RNA is instantly observable.
In this study, we wanted to evaluate our experience
in performing RNA-based CPS1 molecular genetic inves-
tigation over the past 15 years. To do so, we investigated
all found CPS1 variants in this period, identified with
varying methods, and analyzed the sensitivity of the
applied approaches. We hypothesized that RNA analysis
would reduce the number of missed mutations if com-
pared to direct Sanger sequencing, and would even be
better than NGS techniques.
2 | MATERIALS AND METHODS
From 2004 to 2018, a total of 297 samples were referred
with a suspicion of CPS1D (analyses were done at the
University Children's Hospital Münster, Germany, until
2008, and at the University Children's Hospital Zurich
since 2008). From (index) patients, our laboratory
received mainly cultured fibroblasts or heparin blood,
but also EDTA blood for DNA isolation, DNA, dried
blood spots, or shock-frozen liver tissue. Parents' sam-
ples were used in case the index patient was deceased
and no material was available, and/or for confirmation
of obligate heterozygosity. From the referring letter, we
tried to collect information on origin of patients, onset
of disease, and severity of the clinical course. As molec-
ular genetic investigation was part of clinical diagnos-
tics, there was no requirement for an approval by the
respective ethics committees.
Assuming that single nucleotide changes in exons or
flanking intronic sequences would not pose a problem
for neither of the sequencing methods, we focused our
analysis on complex mutations including intronic
changes possibly affecting splicing as well as deletions,
insertions, and INDELs. Four different sequencing
methods were considered: direct Sanger sequencing of
DNA isolated from EDTA blood or dried blood spots,
NGS without or with CNV, and RNA sequencing using
liver, fibroblasts, or lymphocytes. We arbitrarily defined
±50 bp flanking the exons as limit for an in general
“probably detected” change with however maybe uncer-
tain interpretation. For analyzing splicing variants within
these limits, softwares Human Splicing Finder and
MutationTaster were used.20,21
3 | RESULTS
During the study period, 297 samples were sent from
37 countries in Europe, North and South America,
Australia, Asia, and Africa. CPS1D could be confirmed in
155 patients (52 diagnosed in Münster and 103 in Zurich)
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from 33 countries; patients referred from France (n = 32)
and Turkey (n = 27) comprised the largest groups of posi-
tive samples. For the confirmed cases, we received
mainly fibroblasts (n = 79) or heparin blood (n = 57) for
index patient testing, but also two liver biopsies. In
17 families, there was no sufficient material available
from the index patient. Therefore, mutations were ini-
tially searched for in parents (16 heparin blood samples
and 1 fibroblast cell line), and were, whenever possible,
confirmed in DNA (often derived from dried blood spots)
of the patient.
Clinical information was not always provided, but
the majority of the patients showed a neonatal onset.
No strict correlation was found between type of muta-
tion and onset of disease,11 except for a deletion in
exon 25 (c.3037_3039delGTG) that was always associ-
ated with a neonatal onset of severe disease.22 Of
the total 155 patients, 83 were homozygous but
clinical information was too scarce to further correlate
this. The remaining 72 patients were compound
heterozygous.
Underlining genetic heterogeneity at the CPS1 locus,
we identified a total of 136 different genotypes with
172 different variants, of which 56% were missense
(n = 97), 17% deletions (n = 29), 15% splice-site (n = 26),
6% nonsense (n = 10), 4% insertions (n = 7), and 2%
INDELs (n = 3; Figure 1 and Table 1). Of the total 172 dif-
ferent variants, 31 missense, 2 nonsense, 13 splice-errors,
and 16 Del/Ins/Dup were not yet reported in literature
(summarized in Tables S1 and S2).
The most frequent mutation in this study, present in
17 Turkish patients, was the homozygous deletion in
exon 25 c.3037_3039delGTG (p.Val1013del). Next, the
missense mutation c.2339G>A (p.Arg780His) in exon
19 was found in seven patients (of varying ethnic
background and nationality), of which two are homozy-
gous for this change. The most frequent splice-site muta-
tion was c.3558+1G>C (p.Glu1161_Arg1186del) in exon
29, identified in three patients.
As reported before,11 distribution of CPS1 mutations
shows predominance of the catalytic domains (116 of
172 mutations): the bicarbonate phosphorylation domain
(exons 13-20) was affected by 61 mutations and the carba-
mate phosphorylation domain (exons 25-34) by 55 muta-
tions (Figure 2).
Parental DNA could be investigated in 98 families
confirming obligate carriership in 93 parents. In five fam-
ilies, only one of the parents was found to be a carrier,
namely in three parents only the mother and in two par-
ents only the father.
We identified and further analyzed 14 complex
mutations (ie, intronic changes possibly affecting splic-
ing, deletions, insertions, and INDELs), which were all
found in single patients only and contributed to 14 dif-
ferent genotypes; within this subcohort, only three
patients were homozygous. Details to the complex
mutations in this study are summarized in Table 2.
From these 14 complex mutations, using exon-wise
sequencing or NGS without CNV, five mutations
would have been missed; using NGS even with CNV,
two mutations would have been missed. RNA analysis
did in fact identify all these mutations, and was neces-
sary for a correct interpretation in half of the cases
(Table 2).
FIGURE 1 Graph showing the distribution of all CPS1
mutations in this study
TABLE 1 Summary of CPS1 mutations of the study cohort
Item #
Index patients 155
Genotypes
Homozygous 64
Heterozygous-compound 72
Total 136
Recurrent 1
Mutations
Missense 97
Nonsense 10
Splice-errors 26
Deletions 29
Insertions/duplications 7
Del_Ins 3
Total mutations 172
Recurrent 9
Note: Recurrence of genotypes or mutations in this study was defined as
occurrence >2 times.
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4 | DISCUSSION
CPS1D is a rare metabolic condition with a nonspecific
biochemical profile thus requiring additional tests.5 Now-
adays, confirmation of the disease is usually done by
molecular genetic investigation that led to the reporting
of more than 230 CPS1 mutations underlining the genetic
heterogeneity at this locus.7-14 In recent years, NGS
became the preferred method for CPS1 molecular genetic
investigation either as part of (often custom-made) gene
panels or of whole exome or genome sequencing. In our
laboratory, RNA sequencing was the preferred method in
the past 15 years.11,16 In this study, we investigated retro-
spectively the theoretical sensitivity if different sequenc-
ing approaches would have been used for detecting CPS1
mutations, and, based on our findings, suggest a diagnos-
tic algorithm for molecular genetic testing of CPS1D.
We based our analysis on 155 genetically confirmed
cases comprising 172 different variants and 136 different
genotypes. Main finding was that in CPS1D, private
mutations are the rule, and in about 10% of the genotypes
a complex mutation is present. Underlining the relevance
of RNA sequencing, 7/14 complex mutations required for
correct interpretation RNA analysis, and 5/14 complex
mutations would have been missed if NGS was done
without CNV analysis. In contrast, RNA sequencing had
identified all mutations.
Almost all of the potentially missed variants are
intronic substitutions, deletions, or insertions affecting
splicing. For instance, the deep intronic change
c.3559-745A>G creates a novel donor splice site lead-
ing to an insertion of a 94 bp pseudoexon with a prema-
ture termination codon (p.[Arg1186_Val1187insLysPro
ArgLeuSerLys*]). The same occurred in the case of
c.4102-239A>G (p.[Gln1368Serfs*15]). As both these
mutations lie in deep intronic sequences, likely neither
direct Sanger sequencing nor NGS (with or without
CNV) would have detected them. In contrast, RNA analy-
sis using phytohemagglutinin stimulated lymphocytes or
fibroblasts did in fact identify these mutations. Other
examples illustrating the same principle are summarized
in Table 2. Some of these additional examples comprise
deletions (c.622-52_711+1416del, c.712-430_766del, c.2895
+429_2960-281del), which would have only been detected
if CNV analysis was added to NGS. RNA analysis is how-
ever also important in case of changes close to the exonic
sequences. As shown for mutation c.622-24A>G, while
this change would have likely been identified by all
sequencing methods (apart possibly from whole exome
sequencing), correct interpretation as a splicing mutation
was not offered by in silico prediction (Table 2).
We had previously shown that RNA analysis can sub-
stantially shorten the time to diagnosis in CPS1D.16 We
add here an improved diagnostic yield as another benefit
of performing RNA analysis. With these two advantages
in mind, we propose to consider adding RNA sequencing
in so far mutation-negative patients with a strong suspi-
cion for CPS1D. In addition, it needs to be remembered
FIGURE 2 Distribution of mutations over the CPS1 gene and its domains
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that RNA sequencing is a straightforward and easy to
perform analysis requiring only basic sequencing facili-
ties but not high-throughput techniques rendering esta-
blishing and performing this method feasible in many
places. Based on these findings and considerations, we
propose the following diagnostic algorithm: if available,
RNA sequencing can be the first line genetic test in
suspected CPS1D; in all other cases, NGS together with
CNV should be performed with the option of adding
RNA sequencing in mutation-negative patients with a
strong suspicion for CPS1D or in order to correctly inter-
pret unclear intronic alterations that could possibly affect
splicing.
In summary, molecular genetic investigation for
CPS1D remains challenging as the specific locus shows
a high variability with most mutations being private.
In addition, many intronic sequences of CPS1 are like-
wise prone to changes that may be missed with NGS,
even if CNV analysis is added. Unclear cases may
therefore need to be investigated by RNA sequencing
in addition, if this method is not used as the initial
diagnostic procedure.
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